ClinicalTrials.gg
Sign In
RecruitingNCT07276321Updated Sep 2, 2026

Preliminary Efficacy of an mHealth Intervention in West Africa

An interventional study of G-FOCUS in Psychosis, sponsored by University of Washington. Recruiting at 1 site in Ghana. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by University of Washington · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The investigators are conducting a pilot feasibility and preliminary efficacy trial of a digital intervention for serious mental illness in West Africa.

Participants will be recruited from a large psychiatric hospital in Ghana and will be asked to use a digital intervention titled G-FOCUS.

02

Conditions studied

  • Psychosis

Browse trials for

03

In context

Psychotic Disorders

1,587 studies on the registry are indexed under Psychotic Disorders; 281 are open to participants now.

This study's planned enrollment of 50 is below the median of 65 across 1,320 interventional studies indexed under Psychotic Disorders.

Browse Psychotic Disorders studies →

Lead sponsor

University of Washington is the lead sponsor of 1,433 studies on the registry; 225 are open to participants now.

Of its 158 completed or terminated interventional studies of FDA-regulated products, 136 (86%) have results posted.

Browse University of Washington studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years of age or older
  2. Speaks English
  3. Outpatient receiving care at Accra Psychiatric Hospital
  4. Diagnosis of psychosis and are currently symptomatic as assessed by administering the psychosis section of the MINI (Mini International Neuropsychiatric Interview)
  5. Owns a mobile device capable of downloading smartphone applications

Exclusion criteria

Exclusion Criteria:

  1. Hearing, vision, or motor impairment that would hamper their ability to participate in data collection
  2. Serious intellectual or developmental disability that would hamper their ability to participate in data collection
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    G-FOCUS

    Other: G-FOCUS

Interventions

  • OtherG-FOCUS

    A cultural adaption of an evidence-based (USA populations tested) digital tool for serious mental illness

06

What researchers measure

Primary outcomes

  1. Patient Health Questionnaire-9 (PHQ-9)

    Depressive symptoms.

    Time frame: Baseline, 6 weeks, 12 weeks

  2. Generalized Anxiety Disorder 7-item (GAD-7)

    Anxiety severity

    Time frame: Baseline, 6 weeks, 12 weeks

  3. Revised Green et al Paranoid Thoughts Scale

    Time frame: Baseline, 6 weeks, 12 weeks

  4. Hamilton Program for Schizophrenia Voices Questionnaire

    Time frame: Baseline, 6 weeks, 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Accra Psychiatric Hospital
    Accra, Ghana
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Aug 2027, 21 months after the start.

Of 455 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 21 months is below that.

Counting every sponsor, half of 457 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Dec 11, 2025
StartActual
Nov 3, 2025
Primary completionEst.
Aug 30, 2027
CompletionEst.
Aug 30, 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07276321
Lead sponsor
University of Washington
Responsible party
Dror Ben-Zeev (Professor: School of Medicine, Psychiatry and Behavioral Sciences, University of Washington) — Principal investigator
First posted
Dec 11, 2025
Start date
Nov 3, 2025
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Shalynn Howard
Contact
shahow@uw.edu
253 261-8661
Alexa Beaulieu
Contact
beaulia@uw.edu
253 261-8661
Dror Ben-Zeev, PhD
principal investigator · University of Washington

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Psychotic Disorders →

Other studies from this sponsor

University of Washington →

Start the discussion